
AN2 Therapeutics Shares EBO-301 Phase 3 Data, Boron Pipeline Outlook
AN2 Therapeutics Reports Phase 3 Data from EBO-301 Trial and Details Strategic Pipeline Advancements Across Boron Chemistry Platform AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company pioneering boron-based small molecule therapeutics, has announced topline results from the truncated Phase…












